EUB0000178b_STK3

Screened at 1 µM, S(10) = 0.05, closest targets as % of contr.: ABL (M351T phosph.) (5.5%), ABL (Q252H phosph.) (6.8%), ABL (T315I phosph.) (1.6%), AURKA (0.05%), AURKB (3.4%), DCAMKL1 (8.3%), MAP3K2 (2.6%), MAP3K3 (2%), JAK1 (JH2 pseudokinase domain) (4.3%), STK24 (0.9%), STK26 (0.6%), PIK3CG (0.15%), PIP5K1C (10%), PIP5K2C (8%), RIPK4 (9.5%), TAOK1 (2.6%), TAOK2 (3.4%), TAOK3 (4.5%), TYK2 (JH1 catalytic domain, 2.7%), ULK2 (4.8%); Follow-up Kds and IC50s: Kd/IC50(ABL, M351T phosph.) = 42/ 17.6 nM, KD/IC50(ABL (Q252H phosph.) = 24/ 11.6 nM, Kd/IC50(ABL, T315I phosph.) = 14/ 16.6 nM, Kd/IC50 (AURKA) = 13/ 19.4 nM, Kd/IC50(AURKB) = 40/ 19.4 nM, Kd/IC50(DCAMKL1) = 25/ 27.9 nM, Kd/IC50(MAP3K2) = 19/ 79.6 nM, Kd/IC50(MAP3K3) = 27/ 38.4 nM, Kd/IC50(JAK1, JH2 pseudokinase domain) = 22/ 38.7 nM, Kd/IC50(STK24) = 18/ 44.8 nM, Kd/IC50(STK26) = 16/ 27.3 nM, Kd/IC50(PIK3CG) = 4.8/ 38.4 nM, Kd/IC50(PIP5K1C) = 77/ 436 nM, Kd(PIP5K2C) = 34 nM, Kd(RIPK4) = 140 nM, Kd/IC50(TAOK1) = 180/ 165 nM, Kd/IC50(TAOK2) = 100/ 134 nM, Kd/IC50(TAOK3) = 610/ 254 nM, Kd/IC50(TYK2, JH1 catalytic domain) = 610/ 254 nM, Kd/IC50(ULK2) = 35/ 41.5 nM;